1
|
|
2
|
Reyes Díaz LM, Lastre González MDSJB, Cuello M, Sierra-González VG, Ramos Pupo R, Lantero MI, Harandi AM, Black S, Pérez O. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea. Pediatr Infect Dis J 2021; 40:375-381. [PMID: 33591079 DOI: 10.1097/inf.0000000000003047] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Overall, there are over 30 different sexually transmitted infections with Neisseria gonorrhoeae being the third most frequent with a reported 78 million cases per year. Gonococcal infection causes genital inflammation, which can be a risk factor for others sexually transmitted infections, particularly human immunodeficiency virus. Gonorrhea is a treatable disease, but recently an increase in antibiotic resistance has been of concern. There are currently no vaccines available. However, parenteral vaccination with anti N. meningitidis serogroup B vaccine has been reported to decrease the incidence of gonococcal burden in New Zealand and in Cuba despite the fact that parenteral vaccination is not deemed to induce mucosal IgA. Here we explore possible mechanisms of protection against gonococcal infection through parenteral meningococcal B vaccination. METHODS Ninety-two serum, saliva and oropharyngeal swabs samples of young adults (healthy and Neisseria carriers) of the internal higher school were obtained. They have been vaccinated with VA-MENGOC-BC (MBV) during their infancy and boosted with a third dose during this study. Serum and saliva samples were analyzed by ELISA and Western blot to measured IgG and IgA antibodies against N. meningitidis and N. gonorrhoeae antigens. N. meningitidis carriers were determined by standard microbiologic test. In addition, we reviewed epidemiologic data for N. meningitidis and N. gonorrhoeae infections in Cuba. RESULTS Epidemiologic data show the influence of MBV over gonorrhea incidence suggesting to be dependent of sexual arrival age of vaccines but not over syphilis. Laboratorial data permit the detection of 70 and 22 noncarriers and carriers of N. meningitidis, respectively. Serum anti-MBV antigens (PL) responses were boosted by a third dose and were independent of carriage stages, but saliva anti-PL IgA responses were only present and were significant induced in carriers subjects. Carriers boosted with a third dose of MBV induced similar antigonococcal and -PL saliva IgA and serum IgG responses; meanwhile, serum antigonococcal IgG was significantly lower. In saliva, at least 2 gonococcal antigens were identified by Western blot. Finally, gonococcal-specific mucosal IgA antibody responses, in addition to the serum IgG antibodies, might contributed to the reduction of the incidence of N. gonorrhoeae. We hypothesize that this might have contributed to the observed reductions of the incidence of N. gonorrhoeae. CONCLUSION These results suggest a mechanism for the influence of a Proteoliposome-based meningococcal BC vaccine on gonococcal incidence.
Collapse
Affiliation(s)
- Laura M Reyes Díaz
- From the Instituto de Ciencias Básicas y Preclínicas "Victoria de Girón," Havana, Cuba
| | | | - Maribel Cuello
- Facultad de Ingenierías, Universidad Técnica "Luis Vargas Torres" de Esmeraldas, Esmeralda, Ecuador
| | | | - Raúl Ramos Pupo
- Immunology Department, Instituto de Ciencias Básicas y Preclínicas "Victoria de Girón," Havana, Cuba
- Biomedical Research Institute (BIOMED), Faculty of Medicine and Life Science, Hasselt University, Hasselt, Belgium
| | | | - Ali M Harandi
- Department of Microbiology & Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Vaccine Evaluation Center, British Columbia Children's Hospital Research Institute, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Steven Black
- Cincinnati Children's Hospital, Cincinnati, Ohio
| | - Oliver Pérez
- From the Instituto de Ciencias Básicas y Preclínicas "Victoria de Girón," Havana, Cuba
- Latin American and Caribean Association of Immunology (ALACI), Havana, Cuba
| |
Collapse
|
3
|
Cheng L, Liu WL, Tsou YT, Li JC, Chien CH, Su MP, Liu KL, Huang YL, Wu SC, Tsai JJ, Hsieh SL, Chen CH. Transgenic Expression of Human C-Type Lectin Protein CLEC18A Reduces Dengue Virus Type 2 Infectivity in Aedes aegypti. Front Immunol 2021; 12:640367. [PMID: 33767710 PMCID: PMC7985527 DOI: 10.3389/fimmu.2021.640367] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 02/17/2021] [Indexed: 01/15/2023] Open
Abstract
The C-type lectins, one family of lectins featuring carbohydrate binding domains which participate in a variety of bioprocesses in both humans and mosquitoes, including immune response, are known to target DENV. A human C-type lectin protein CLEC18A in particular shows extensive glycan binding abilities and correlates with type-I interferon expression, making CLEC18A a potential player in innate immune responses to DENV infection; this potential may provide additional regulatory point in improving mosquito immunity. Here, we established for the first time a transgenic Aedes aegypti line that expresses human CLEC18A. This expression enhanced the Toll immune pathway responses to DENV infection. Furthermore, viral genome and virus titers were reduced by 70% in the midgut of transgenic mosquitoes. We found significant changes in the composition of the midgut microbiome in CLEC18A expressing mosquitoes, which may result from the Toll pathway enhancement and contribute to DENV inhibition. Transgenic mosquito lines offer a compelling option for studying DENV pathogenesis, and our analyses indicate that modifying the mosquito immune system via expression of a human immune gene can significantly reduce DENV infection.
Collapse
Affiliation(s)
- Lie Cheng
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.,Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - Wei-Liang Liu
- National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Miaoli, Taiwan
| | - Yun-Ting Tsou
- Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei, Taiwan
| | - Jian-Chiuan Li
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan
| | - Chia-Hao Chien
- Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan
| | - Matthew P Su
- Department of Biological Science, Nagoya University, Nagoya, Japan
| | - Kun-Lin Liu
- National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Miaoli, Taiwan
| | - Ya-Lang Huang
- Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - Shih-Cheng Wu
- National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Miaoli, Taiwan
| | - Jih-Jin Tsai
- Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.,Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.,School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Shie-Liang Hsieh
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.,Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.,Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute for Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan
| | - Chun-Hong Chen
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.,National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Miaoli, Taiwan
| |
Collapse
|
4
|
Lee ALZ, Yang C, Gao S, Wang Y, Hedrick JL, Yang YY. Biodegradable Cationic Polycarbonates as Vaccine Adjuvants. ACS APPLIED MATERIALS & INTERFACES 2020; 12:52285-52297. [PMID: 33179910 DOI: 10.1021/acsami.0c09649] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
In this study, biodegradable cationic polycarbonate and polylactide block copolymers were synthesized and successfully used as novel vaccine adjuvants to provide enhanced anticancer immunity. The polymers formed nanoparticles with the model vaccine, ovalbumin (OVA), and the immunostimulant toll-like receptor 3 agonist poly(I:C) (a synthetic analog of the double-stranded RNA). Higher uptake of poly(I:C) by the bone marrow-derived dendritic cells and macrophages and OVA by dendritic cells was observed when delivered using the polymer adjuvant. In vivo experiments showed that these nanoparticles remained longer in the subcutaneous injection site as compared to OVA alone and led to higher production of anti-OVA specific antibodies with prolonged immunostimulation. When OVA was combined with poly(I:C) that was either co-entrapped in the same particles or as separate particles, a comparable level of anti-OVA IgG1 antibodies and interleukin-6 (IL-6) was produced in mouse blood plasma, and a similar level of cytotoxic T lymphocyte (CTL) response in mice was stimulated as compared to OVA/Alum particles. Furthermore, tumor rejection in the mice that were vaccinated for 9 months with the formulations containing the polymer adjuvant was stronger than the other treatment groups without the polymer. Notably, the cationic polycarbonates were not associated with any adverse in vivo effects. Thus, these biodegradable polymers may be promising substitutes for aluminum-based adjuvants in vaccine formulations.
Collapse
Affiliation(s)
- Ashlynn L Z Lee
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669, Singapore
| | - Chuan Yang
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669, Singapore
| | - Shujun Gao
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669, Singapore
- NanoBio Lab, 31 Biopolis Way, #09-01 The Nanos, Singapore 138669, Singapore
| | - Yanming Wang
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669, Singapore
| | - James L Hedrick
- IBM Almaden Research Center, 650 Harry Road, San Jose, California 95120 United States
| | - Yi Yan Yang
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669, Singapore
| |
Collapse
|
5
|
Machín L, Tamargo B, Piñón A, Atíes RC, Scull R, Setzer WN, Monzote L. Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) Essential Oils Formulated in Nanocochleates against Leishmania amazonensis. Molecules 2019; 24:E4222. [PMID: 31757083 PMCID: PMC6930544 DOI: 10.3390/molecules24234222] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 11/01/2019] [Accepted: 11/06/2019] [Indexed: 01/19/2023] Open
Abstract
Leishmaniasis is a group of neglected tropical diseases caused by protozoan parasites of the Leishmania genus. The absence of effective vaccines and the limitations of current treatments make the search for effective therapies a real need. Different plant-derived essential oils (EOs) have shown antileishmanial effects, in particular from Bixa orellana L. (EO-Bo) and Dysphania ambrosioides (L.) Mosyakin & Clemants (EO-Da). In the present study, the EO-Bo and EO-Da, formulated in nanocochleates (EO-Bo-NC and EO-Da-NC, respectively), were evaluated in vitro and in vivo against L. amazonensis. The EO-Bo-NC and EO-Da-NC did not increase the in vitro inhibitory activity of the EOs, although the EO-Bo-NC showed reduced cytotoxic effects. In the animal model, both formulations (30 mg/kg/intralesional route/every 4 days/4 times) showed no deaths or weight loss greater than 10%. In the animal (mouse) model, EO-Bo-NC contributed to the control of infection (p < 0.05) in comparison with EO-Bo treatment, while the mice treated with EO-Da-NC exhibited larger lesions (p < 0.05) compared to those treated with EO-Da. The enhanced in vivo activity observed for EO-Bo-NC suggests that lipid-based nanoformulations like nanocochleates should be explored for their potential in the proper delivery of drugs, and in particular, the delivery of hydrophobic materials for effective cutaneous leishmaniasis treatment.
Collapse
Affiliation(s)
- Laura Machín
- Department of Pharmacy, Institute of Pharmacy and Food, Havana University, Havana 17100, Cuba; (L.M.); (R.C.A.); (R.S.)
| | - Beatriz Tamargo
- Department of Physiological Science, Latin American School of Medical Sciences, Havana 11300, Cuba;
| | - Abel Piñón
- Department of Parasitology, Institute of Tropical Medicine Pedro Kourí, Havana 17100, Cuba;
| | - Regla C. Atíes
- Department of Pharmacy, Institute of Pharmacy and Food, Havana University, Havana 17100, Cuba; (L.M.); (R.C.A.); (R.S.)
| | - Ramón Scull
- Department of Pharmacy, Institute of Pharmacy and Food, Havana University, Havana 17100, Cuba; (L.M.); (R.C.A.); (R.S.)
| | - William N. Setzer
- Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA
- Aromatic Plant Research Center, 230 N 1200 E, Suite 100, Lehi, UT 84043, USA
- Research Network: Natural Products against Neglected Diseases (ResNet NPND)
| | - Lianet Monzote
- Department of Parasitology, Institute of Tropical Medicine Pedro Kourí, Havana 17100, Cuba;
- Research Network: Natural Products against Neglected Diseases (ResNet NPND)
| |
Collapse
|
6
|
Fraleigh NL, Oliva R, Lewicky JD, Martel AL, Acevedo R, Dagmar GR, Le HT. Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes. PLoS One 2019; 14:e0221708. [PMID: 31442285 PMCID: PMC6707630 DOI: 10.1371/journal.pone.0221708] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Accepted: 08/13/2019] [Indexed: 12/19/2022] Open
Abstract
Despite the increased risks of cancers and cardiovascular related diseases, tobacco smoking continues to be prevalent in the population due largely in part to the addictive nature of nicotine. Nicotine vaccines are an attractive alternative to the current smoking cessation options but have yet to be successful enough in clinical trials to reach the market due to a lack of neutralizing antibodies and inconsistent results. Using AFPL1 derived from the Cuban meningococcal vaccine as an adjuvant, we have previously published promising results with an intranasally administered nicotine vaccine. In order to examine the immunogenicity and safety of this vaccine in mice we set up a pilot trial administering the vaccine either intranasally, intramuscularly or utilizing both routes simultaneously and evaluated immune responses and clinical symptoms throughout the duration of the vaccination protocol and post-mortem. These data further demonstrate the ability of the AFPL1 nicotine conjugate vaccine to be a safe and potential candidate for clinical use.
Collapse
Affiliation(s)
- Nya L. Fraleigh
- Health Sciences North Research Institute, Sudbury, Ontario, Canada
| | | | | | | | | | | | - Hoang-Thanh Le
- Health Sciences North Research Institute, Sudbury, Ontario, Canada
- Northern Ontario School of Medicine, Medicinal Sciences division, Sudbury, Ontario, Canada
- Chemistry & Biochemistry and Biology Departments, Laurentian university, Sudbury, Ontario, Canada
- * E-mail:
| |
Collapse
|
7
|
Tamargo Santos B, Fleitas Pérez C, Infante Bourzac JF, Márquez Nápoles Y, Ramírez González W, Bourg V, Torralba D, Pérez V, Mouriño A, Ayala J, Labrada Rosado A, Aleya L, Bungau S, Sierra González VG. Remote induction of cellular immune response in mice by anti-meningococcal nanocochleates - nanoproteoliposomes. THE SCIENCE OF THE TOTAL ENVIRONMENT 2019; 668:1055-1063. [PMID: 31018447 DOI: 10.1016/j.scitotenv.2019.03.075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 03/05/2019] [Accepted: 03/05/2019] [Indexed: 06/09/2023]
Abstract
New adjuvant formulations, based on proteoliposomes <40 nm and cochleates <100 nm, without Al(OH)3 adjuvant, were evaluated regarding their ability to generate Th1 immune response through a Delayed -Type Hypersensitivity Test, at the mouse model, by using a Neisseria meningitidis B protein complex as antigen. The formulations were administered by intramuscular (IM) (2 inoculations - at baseline and after 14 days) and intranasal (IN) (3 inoculations at 7 days) immunization pathways. All IM immunized groups were able to induce similar response to these formulations as well as to VA-MENGOC-BC® vaccine - containing Al(OH)3 adjuvant (used as positive control of the trial). In all groups, the induced inflammation (IP) rate was statistically higher than in the negative control group (CN) (p < 0.05). Immunogenicity, measured by HSR and CD4+ lymphocyte increase was equivalent to the control vaccine and most important, granuloma reactogenicity at the site of injection was eliminated, fact demonstrated by histological study. All groups of animals immunized by IN route showed HSR reactions and statistically significant differences with respect to the CN group. However, IP values were lower, with statistical differences (p < 0.05) for the same adjuvant formulation IM administered, except the AIF2-nCh formulation that generated statistically similar induction (p > 0.05) by both immunization pathways, suggesting it to be the best candidate for the next IN trial. Proteoliposome and cochleate formulations tested were able to mount potent Th-1 immune response, equivalent to the original vaccine formulation, with the advantage of less reactogenicity in the site of the injection, caused by the toxicity of Al(OH)3 adjuvant gel.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Antonio Mouriño
- Santiago de Compostela University, Santiago de Compostela, Spain
| | - Juan Ayala
- Center for Molecular Biology "Severo Ochoa", Madrid, Spain
| | | | - Lotfi Aleya
- Laboratoire Chrono-environnement, Université de Franche-Comté, Besançon, France.
| | - Simona Bungau
- Faculty of Medicine and Pharmacy, University of Oradea, Romania
| | | |
Collapse
|
8
|
Fingermann M, Avila L, De Marco MB, Vázquez L, Di Biase DN, Müller AV, Lescano M, Dokmetjian JC, Fernández Castillo S, Pérez Quiñoy JL. OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves. Hum Vaccin Immunother 2018; 14:2208-2213. [PMID: 29923791 PMCID: PMC6183318 DOI: 10.1080/21645515.2018.1490381] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Strains of Shiga toxin-producing Escherichia coli (STEC) can cause the severe Hemolytic Uremic Syndrome (HUS). Shiga toxins are protein toxins that bind and kill microvascular cells, damaging vital organs. No specific therapeutics or vaccines have been licensed for use in humans yet. The most common route of infection is by consumption of dairy or farm products contaminated with STEC. Domestic cattle colonized by STEC strains represent the main reservoir, and thus a source of contamination. Outer Membrane Vesicles (OMV) obtained after detergent treatment of gram-negative bacteria have been used over the past decades for producing many licensed vaccines. These nanoparticles are not only multi-antigenic in nature but also potent immunopotentiators and immunomodulators. Formulations based on chemical-inactivated OMV (OMVi) obtained from a virulent STEC strain (O157:H7 serotype) were found to protect against pathogenicity in a murine model and to be immunogenic in calves. These initial studies suggest that STEC-derived OMV has a potential for the formulation of both human and veterinary vaccines.
Collapse
Affiliation(s)
| | - Lucía Avila
- a INPB, ANLIS "Dr. Carlos G. Malbrán" , Buenos Aires , Argentina
| | | | - Luciana Vázquez
- b UOCCB, ANLIS "Dr. Carlos G. Malbrán" , Buenos Aires , Argentina
| | | | | | - Mirta Lescano
- a INPB, ANLIS "Dr. Carlos G. Malbrán" , Buenos Aires , Argentina
| | | | | | | |
Collapse
|
9
|
Dispersion and stabilization of cochleate nanoparticles. Eur J Pharm Biopharm 2017; 117:270-275. [DOI: 10.1016/j.ejpb.2017.04.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 03/28/2017] [Accepted: 04/27/2017] [Indexed: 11/19/2022]
|
10
|
Tamargo B, Monzote L, Piñón A, Machín L, García M, Scull R, Setzer WN. In Vitro and In Vivo Evaluation of Essential Oil from Artemisia absinthium L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. MEDICINES 2017; 4:medicines4020038. [PMID: 28930253 PMCID: PMC5590074 DOI: 10.3390/medicines4020038] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 05/26/2017] [Accepted: 06/05/2017] [Indexed: 12/15/2022]
Abstract
Background: Leishmaniasis is a zoonotic disease caused by protozoan parasites from Leishmania genus. Currently, there are no effective vaccines available and the available therapies are far from ideal. In particular, the development of new therapeutic strategies to reduce the infection caused by Leishmania amazonensis could be considered desirable. Different plant-derived products have demonstrated antileishmanial activity, including the essential oil (EO) from Artemisia absinthium L. (EO-Aa), Asteraceae. Methods: In the present study, the EO-Aa formulated in nanocochleates (EO-Aa-NC) was investigated in vitro against intracellular amastigotes of L. amazonensis and non-infected macrophages from BALB/c mice. In addition, the EO-Aa-NC was also evaluated in vivo against on experimental cutaneous leishmaniasis, which body weight, lesion progression, and parasite load were determined. Results: EO-Aa-NC displayed IC50 values of 21.5 ± 2.5 μg/mL and 27.7 ± 5.6 μg/mL against intracellular amastigotes of L. amazonensis and non-infected peritoneal macrophage, respectively. In the animal model, the EO-Aa-NC (30 mg/kg/intralesional route/every 4 days 4 times) showed no deaths or weight loss greater than 10%. In parallel, the EO-Aa-NC suppressed the infection in the murine model by approximately 50%, which was statistically superior (p < 0.05) than controls and mice treated with EO-Aa. In comparison with Glucantime®, EO-Aa-NC inhibited the progression of infection as efficiently (p > 0.05) as administration of the reference drug. Conclusions: Encochleation of EO-Aa resulted in a stable, tolerable, and efficacious antileishmanial formulation, facilitating systemic delivery of EO, with increased activity compared to administration of the free EO-Aa. This new formulation shows promising potential to future studies aimed at a new therapeutic strategy to treat leishmaniasis.
Collapse
Affiliation(s)
- Beatriz Tamargo
- Department of Pharmacology, Institute of Pharmacy and Food, Havana University, Havana 10400, Cuba.
| | - Lianet Monzote
- Parasitology Department, Institute of Tropical Medicine Pedro Kouri, Havana 10400, Cuba.
| | - Abel Piñón
- Parasitology Department, Institute of Tropical Medicine Pedro Kouri, Havana 10400, Cuba.
| | - Laura Machín
- Department of Pharmacology, Institute of Pharmacy and Food, Havana University, Havana 10400, Cuba.
| | - Marley García
- Parasitology Department, Institute of Tropical Medicine Pedro Kouri, Havana 10400, Cuba.
| | - Ramón Scull
- Department of Chemistry, Institute of Pharmacy and Food, Havana University, Havana 10400, Cuba.
| | - William N Setzer
- Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA.
| |
Collapse
|
11
|
Fraleigh NL, Boudreau J, Bhardwaj N, Eng NF, Murad Y, Lafrenie R, Acevedo R, Oliva R, Diaz-Mitoma F, Le HT. Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1). Heliyon 2016; 2:e00147. [PMID: 27622215 PMCID: PMC5008958 DOI: 10.1016/j.heliyon.2016.e00147] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 07/25/2016] [Accepted: 08/19/2016] [Indexed: 12/05/2022] Open
Abstract
Tobacco smoking is recognized as a global pandemic resulting in 6 million deaths per year. Despite a variety of anti-smoking products available to aid with tobacco cessation, the majority of people who attempt to quit smoking relapse within 6 months due to the addictive nature of nicotine. An immunotherapy approach could offer a promising treatment option by inducing a potent selective antibody response against nicotine in order to block its distribution to the brain and its addictive effects in the central nervous system. Our nicotine vaccine candidate was administered intranasally using the Neisseria meningitidis serogroup B Adjuvant Finlay Proteoliposome 1 (AFPL1) as a part of the delivery system. This system was designed to generate a robust immune response by stimulating IL-1β production through Toll-like receptor 4 (TLR4), a potent mechanism for mucosal immunity. The vaccine induced high antibody titers in mice sera in addition to inducing mucosal antibodies. The efficacy of our vaccine was demonstrated using in vivo challenge experiments with radioactive [3H]-nicotine, followed by an analysis of nicotine distribution in the lung, liver, blood and brain. Our results were encouraging as the nicotine concentration in the brain tissue of mice vaccinated with our candidate vaccine was four times lower than in non-vaccinated controls; suggesting that the anti-nicotine antibodies were able to block nicotine from crossing the blood brain barrier. In summary, we have developed a novel nicotine vaccine for the treatment of tobacco addiction by intranasal administration and also demonstrated that the AFPL1 can be used as a potential adjuvant for this vaccine design.
Collapse
Affiliation(s)
- Nya L. Fraleigh
- Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
| | - Justin Boudreau
- Laurentian University, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
| | - Nitin Bhardwaj
- Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
| | - Nelson F. Eng
- Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
| | - Yanal Murad
- Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
| | - Robert Lafrenie
- Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
- Laurentian University, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
- Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
| | - Reinaldo Acevedo
- Finlay Vaccine Institute, Ave. 27 No. 19805, La Habana, AP 16017, Cuba
| | - Reynaldo Oliva
- Finlay Vaccine Institute, Ave. 27 No. 19805, La Habana, AP 16017, Cuba
| | - Francisco Diaz-Mitoma
- Laurentian University, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
- Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
| | - Hoang-Thanh Le
- Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
- Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
- Corresponding author.
| |
Collapse
|
12
|
Tirado Y, Puig A, Alvarez N, Borrero R, Aguilar A, Camacho F, Reyes F, Fernandez S, Perez JL, Acevedo R, Mata Espinoza D, Payan JAB, Garcia MDLA, Kadir R, Sarmiento ME, Hernandez-Pando R, Norazmi MN, Acosta A. Mycobacterium smegmatis proteoliposome induce protection in a murine progressive pulmonary tuberculosis model. Tuberculosis (Edinb) 2016; 101:44-48. [PMID: 27865396 DOI: 10.1016/j.tube.2016.07.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2016] [Revised: 07/28/2016] [Accepted: 07/31/2016] [Indexed: 11/18/2022]
Abstract
Tuberculosis (TB) remains an important cause of mortality and morbidity. The TB vaccine, BCG, is not fully protective against the adult form of the disease and is unable to prevent its transmission although it is still useful against severe childhood TB. Hence, the search for new vaccines is of great interest. In a previous study, we have shown that proteoliposomes obtained from Mycobacterium smegmatis (PLMs) induced cross reactive humoral and cellular response against Mycobacterium tuberculosis (Mtb) antigens. With the objective to evaluate the protective capability of PLMs, a murine model of progressive pulmonary TB was used. Animals immunized with PLMs with and without alum (PLMs/PLMsAL respectively) showed protection compared to non-immunized animals. Mice immunized with PLMsAL induced similar protection as that of BCG. Animals immunized with BCG, PLMs and PLMsAL showed a significant decrease in tissue damage (percentage of pneumonic area/lung) compared to non-immunized animals, with a more prominent effect in BCG vaccinated mice. The protective effect of the administration of PLMs in mice supports its future evaluation as experimental vaccine candidate against Mtb.
Collapse
MESH Headings
- Adjuvants, Immunologic
- Alum Compounds
- Animals
- BCG Vaccine
- Bacterial Load
- Disease Models, Animal
- Disease Progression
- Male
- Mice, Inbred BALB C
- Mycobacterium smegmatis/immunology
- Mycobacterium tuberculosis/growth & development
- Mycobacterium tuberculosis/isolation & purification
- Pneumonia, Bacterial/microbiology
- Pneumonia, Bacterial/pathology
- Pneumonia, Bacterial/prevention & control
- Proteolipids/immunology
- Tuberculosis Vaccines
- Tuberculosis, Pulmonary/immunology
- Tuberculosis, Pulmonary/microbiology
- Tuberculosis, Pulmonary/pathology
- Tuberculosis, Pulmonary/prevention & control
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Dulce Mata Espinoza
- Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition "Salvador Zubiran", D.F. Mexico, Mexico
| | - Jorge Alberto Barrios Payan
- Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition "Salvador Zubiran", D.F. Mexico, Mexico
| | | | - Ramlah Kadir
- School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - María E Sarmiento
- School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - Rogelio Hernandez-Pando
- Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition "Salvador Zubiran", D.F. Mexico, Mexico
| | - Mohd-Nor Norazmi
- School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia; INFORMM, Universiti Sains Malaysia, Kelantan, Malaysia.
| | | |
Collapse
|
13
|
Tirado Y, Puig A, Alvarez N, Borrero R, Aguilar A, Camacho F, Reyes F, Fernández S, Pérez JL, Espinoza DM, Payán JAB, Sarmiento ME, Norazmi MN, Hernández-Pando R, Acosta A. Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis. Hum Vaccin Immunother 2015; 11:657-61. [PMID: 25671612 PMCID: PMC4517452 DOI: 10.1080/21645515.2015.1011566] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Tuberculosis (TB) is one of the most important causes of mortality and morbidity due to infectious diseases. BCG, the vaccine in use, is not fully protective against TB. In a previous study, we have shown that proteoliposomes (outer membrane extracts), obtained from BCG (PLBCG) were able to induce humoral immune responses against Mycobacterium tuberculosis (Mtb) antigens. With the objective to evaluate the protective capability of PLBCG alone or as a booster with BCG, a murine model of progressive pulmonary TB was used. Animals immunized with PLBCG adjuvanted with alum (PLBCG-Al) showed similar protection to that conferred by BCG. The group immunized with PLBCG-Al as a booster to BCG gave superior protection than BCG as evidenced by a reduction of bacterial load in lungs 2 months after infection with Mtb. Animals immunized with BCG, PLBCG-Al and this formulation as a booster of BCG, showed a significant decrease of tissue damage (percentage of pneumonic area/lung) compared with non-immunized animals. These results demonstrate that immunization with PLBCG-Al alone or as a booster to BCG induce appropriate protection against challenge with Mtb in mice and support the future evaluation of PLBCG as a promising vaccine candidate against Mtb.
Collapse
|
14
|
Bozó T, Brecska R, Gróf P, Kellermayer MSZ. Extreme resilience in cochleate nanoparticles. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2015; 31:839-845. [PMID: 25521248 DOI: 10.1021/la504428x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Cochleates, prospective nanoscale drug delivery vehicles, are rolls of negatively charged phospholipid membrane layers. The membrane layers are held together by calcium ions; however, neither the magnitude of membrane interaction forces nor the overall mechanical properties of cochleates have been known. Here, we manipulated individual nanoparticles with atomic force microscopy to characterize their nanomechanical behavior. Their stiffness (4.2-12.5 N/m) and membrane-rupture forces (45.3-278 nN) are orders of magnitude greater than those of the tough viral nanoshells. Even though the fundamental building material of cochleates is a fluid membrane, the combination of supramolecular geometry, the cross-linking action of calcium, and the tight packing of the ions apparently lead to extreme mechanical resilience. The supramolecular design of cochleates may provide efficient protection for encapsulated materials and give clues to understanding biomolecular structures of similar design, such as the myelinated axon.
Collapse
Affiliation(s)
- Tamás Bozó
- Department of Biophysics and Radiation Biology, and ‡MTA-SE Molecular Biophysics Research Group, Semmelweis University , Tűzoltó utca 37-47, Budapest 1094, Hungary
| | | | | | | |
Collapse
|
15
|
Romeu B, Lastre M, Reyes L, González E, Borrero Y, Lescaille D, Pérez R, Nuñez D, Pérez O. Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses. Vaccine 2014; 32:6971-6978. [PMID: 25454865 DOI: 10.1016/j.vaccine.2014.10.037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Revised: 09/17/2014] [Accepted: 10/17/2014] [Indexed: 11/25/2022]
Abstract
The response to infection against Salmonella involves both B and T cell mediated immunity. An effective immunization can activate an adequate immune response capable to control the primary infection and protect against a secondary infection. Mucosal vaccination, by inducing local pathogen-specific immune responses, has the potential to counter mucosally transmitted pathogens at the portal of entry, thereby increasing the efficacy of vaccines. The aim of this work was to explore the efficacy of AFCo1 or AFPL1, as mucosal adjuvants to stimulate cell immunity and memory responses against Vi polysaccharide antigen of Salmonella typhi (PsVi). Mice immunized with 3 intranasal doses exhibited high levels of PsVi-specific IgG (p<0.05), IgG2a and IgG2c subclasses. Also, an amplified recall response after a booster immunization with a plain polysaccharide vaccine was induced. Avidities index were higher in mice immunized with adjuvanted formulations at different chaotropic concentrations. Furthermore, IL-12 and IFN-γ levels in nasally vaccinated mice with both adjuvants were induced. Moreover, priming with 3 doses followed by booster immunization with VaxTyVi(®) resulted in high levels of anti-Vi specific IgG, IgG subclasses and antibody avidity. Long lived plasma cells in bone marrow, memory B cells and long-term memory T cells after booster dose were induced. The combined formulation of Vi polysaccharide with mucosal adjuvants provides an improved immunogenicity, in particular with regard to cellular responses and long lasting cells responses.
Collapse
Affiliation(s)
- Belkis Romeu
- Immunology Department, Finlay Institute, Havana, Cuba.
| | - Miriam Lastre
- Immunology Department, Finlay Institute, Havana, Cuba
| | - Laura Reyes
- Immunology Department, Finlay Institute, Havana, Cuba
| | | | | | | | - Rocmira Pérez
- Immunology Department, Finlay Institute, Havana, Cuba
| | - Darzy Nuñez
- Animal Models Group, Direction of Research and Development, Finlay Institute, Havana, Cuba
| | - Oliver Pérez
- Immunology Department, Finlay Institute, Havana, Cuba
| |
Collapse
|
16
|
Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A. Immunol Res 2014; 58:75-85. [PMID: 23660844 DOI: 10.1007/s12026-013-8427-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Outer-membrane vesicles (OMVs) have inherent adjuvant properties, and many vaccines use OMV as vaccine components. Utilizing the adjuvant properties of OMV could lead to the formulation of vaccines that are less expensive and potentially more immunogenic than covalently conjugated polysaccharide vaccines. We evaluated the adjuvant effect in Balb/c mice of combinations of OMV from Neisseria meningitidis serogroup A and W135 as compared to that of the non-covalently conjugated capsular polysaccharide A. Both antigens were adsorbed onto aluminum hydroxide. The mice were given a booster dose of plain polysaccharide A to stimulate an immunologic memory response. Subclasses determination and cytokine assays demonstrated the capacity of OMV to induce a IgG2a/IgG2b isotype profile and IFN-γ production, suggesting the induction of a Th1 pattern immune response. Lymphoproliferative responses to OMVs were high, with affinity maturation of antibodies observed. Bactericidal titers after the booster dose were also observed. Memory B cells and long-term memory T cells were also detected. The results of this study indicate that combined meningococcal serogroup A and W135 OMV can activate cell-mediated immunity and induce a long-term memory response.
Collapse
|
17
|
Gebril A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines 2014; 11:1139-55. [DOI: 10.1586/erv.12.81] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
18
|
Patel GB, Chen W. Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines 2014; 9:431-40. [DOI: 10.1586/erv.10.34] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
19
|
Pérez O, Romeu B, Cabrera O, González E, Batista-Duharte A, Labrada A, Pérez R, Reyes LM, Ramírez W, Sifontes S, Fernández N, Lastre M. Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform. Front Immunol 2013; 4:407. [PMID: 24348475 PMCID: PMC3845353 DOI: 10.3389/fimmu.2013.00407] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Accepted: 11/10/2013] [Indexed: 11/13/2022] Open
Abstract
The development of effective vaccines against neglected diseases, especially those associated with poverty and social deprivation, is urgently needed. Modern vaccine technologies and a better understanding of the immune response have provided scientists with the tools for rational and safer design of subunit vaccines. Often, however, subunit vaccines do not elicit strong immune responses, highlighting the need to incorporate better adjuvants; this step therefore becomes a key factor for vaccine development. In this review we outline some key features of modern vaccinology that are linked with the development of better adjuvants. In line with the increased desire to obtain novel adjuvants for future vaccines, the Finlay Adjuvant Platform offers a novel approach for the development of new and effective adjuvants. The Finlay Adjuvants (AFs), AFPL (proteoliposome), and AFCo (cochleate), were initially designed for parenteral and mucosal applications, and constitute potent adjuvants for the induction of Th1 responses against several antigens. This review summarizes the status of the Finlay technology in producing promising adjuvants for unsolved-vaccine diseases including mucosal approaches and therapeutic vaccines. Ideas related to adjuvant classification, adjuvant selection, and their possible influence on innate recognition via multiple toll-like receptors are also discussed.
Collapse
Affiliation(s)
- Oliver Pérez
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba ; Havana Medical Sciences University , Havana , Cuba
| | - Belkis Romeu
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba
| | - Osmir Cabrera
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba
| | - Elizabeth González
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba
| | - Alexander Batista-Duharte
- Toxicology and Biomedicine Center (TOXIMED), Medical Sciences University Santiago de Cuba , Santiago de Cuba , Cuba
| | - Alexis Labrada
- Centro Nacional de Biopreparados (BioCen) , Mayabeque , Cuba
| | - Rocmira Pérez
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba
| | - Laura M Reyes
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba
| | - Wendy Ramírez
- Centro Nacional de Biopreparados (BioCen) , Mayabeque , Cuba
| | - Sergio Sifontes
- Centro de Bioactivos Químicos (CBQ), Universidad Central Marta Abreu de Las Villas , Villa Clara , Cuba
| | | | - Miriam Lastre
- Immunology Department, Research and Development Vice-presidency, Finlay Institute , Havana , Cuba
| |
Collapse
|
20
|
Fernández S, Fajardo EM, Mandiarote A, Año G, Padrón MA, Acosta M, Cabrera RA, Riverón LA, Álvarez M, Blaín K, Fariñas M, Cardoso D, García LG, Campa C, Pérez JL. A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models. BMC Immunol 2013; 14 Suppl 1:S8. [PMID: 23458724 PMCID: PMC3582456 DOI: 10.1186/1471-2172-14-s1-s8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Whooping cough remains a health problem despite high vaccination coverage. It has been recommended that development of new strategies provide long-lasting immunity. The aim of this work was to evaluate the potential of proteoliposomes (PL) extracted from Bordetella pertussis as a vaccine candidate against whooping cough. The size of the B. pertussis PL was estimated to be 96.7 ± 50.9 nm by Scanning Correlation Spectroscopy and the polydispersity index was 0.268. Western blots using monoclonal antibodies revealed the presence of pertussis toxin, pertactin, and fimbriae 3. The Limulus Amebocyte Lisate (LAL) assay showed endotoxin levels lower than those reported for whole cell pertussis licensed vaccines, while the Pyrogen Test indicated 75 ng/mL/Kg. The PL showed high protection capacity in mouse challenge models. There was 89.7% survival in the intracerebral challenge and total reduction of the number of CFU in the intranasal challenge. No significant differences (p > 0.05) were observed between mice immunized with B. pertussis PL and the Cuban DTwP vaccine, whichever challenge model used. These results encouraged us to continue the development of the B. pertussis PL as a component of a new combined vaccine formulated with tetanus and diphtheria toxoids or as a booster dose for adolescents and adults.
Collapse
Affiliation(s)
- Sonsire Fernández
- Research & Development Vice-presidency, Finlay Institute, Havana, Cuba.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
|
22
|
Nanostructured self assembled lipid materials for drug delivery and tissue engineering. Ther Deliv 2012; 2:1485-516. [PMID: 22826876 DOI: 10.4155/tde.11.105] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Every living organism comprises of lipids as basic building blocks in addition to other components. Utilizing these lipids for pharmaceutical and biomedical applications can overcome biocompatibility and biodegradability issues. A well known example is liposomes (lipids arranged in lamellar structures), but other than that there are additional unique mesophasic structures of lipids formed as a result of lipid polymorphisms, which include cubic-, hexagonal- or sponge-phase structures. These structures provide the advantages of stability and production feasibility compared with liposomes. Cubosomes, which exist in a cubic structure, have improved stability, bioadhesivity and biocompatibility. Hexagonal phases or hexosomes exhibit hexagonal arrangements and can encapsulate different drugs with high stability. Lipids also forms tube-like structures known as tubules and ribbons that are also utilized in different biomedical applications, especially in tissue engineering. Immune stimulating complexes are nanocage-like structures formed as a result of interactions of lipid, antigen and Quillaja saponin. These lipidic mesophasic structures have been utilized for gene, vaccine and drug delivery. This article addresses lipid self-assembled supramolecular nanostructures, including cubosomes, hexosomes, tubules, ribbons, cochleates, lipoplexes and immune stimulating complexes and their biomedical applications.
Collapse
|
23
|
Yu S, Tang C, Shi X, Yang P, Xing L, Wang X. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. Vaccine 2012; 30:5425-36. [DOI: 10.1016/j.vaccine.2012.05.085] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2011] [Revised: 05/28/2012] [Accepted: 05/31/2012] [Indexed: 02/07/2023]
|
24
|
Romeu B, Gonzalez E, Lastre M, Pérez O. Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens? J Drug Target 2012; 20:502-8. [PMID: 22632258 DOI: 10.3109/1061186x.2012.693497] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Vaccination remains the most cost-effective method for preventing infectious diseases. Key to vaccine design is the development of immunological memory, which is an essential property of the adaptive immune system. Bacterial polysaccharide conjugate vaccines are the gold standard currently used to confer protection of the host by inducing humoral immune responses against T-cell-independent antigens. Conjugate vaccines are effective, but we propose that local mucosal immune responses are likely to also play an important role in inducing immunity, and they have been less explored than systemic and adaptive immune responses. Adjuvants have been used to improve the immune response to vaccine antigens, however, no mucosal adjuvant has been licensed for human use. Here we describe the recent progress in the use of mucosal adjuvants to achieve significant immune responses against T-cell-independent antigens. We also introduce the idea that studying the mechanisms that induce cell sub-populations with strong immunological memory may facilitate the design of novel vaccine formulations, in particular in cases of B-cell unresponsiveness to thymus-independent stimuli.
Collapse
Affiliation(s)
- Belkis Romeu
- Immunology Department, Research and Development, Finlay Institute, Havana, Cuba
| | | | | | | |
Collapse
|
25
|
Infante-Bourzac JF, Sifontes-Rodríguez S, Arencibia-Arrebola DF, Hernández-Salazar T, Fariñas-Medina M, Pérez O. Toxicological Assessment of the Cochleate Derived from Neisseria meningitidis Proteoliposome in Sprague Dawley Rats. NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES 2012; 4:135-40. [PMID: 22454827 PMCID: PMC3309621 DOI: 10.4103/1947-2714.93888] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND The AFCo1 cochleate is a potential novel adjuvant derived from Neisseria meningitidis B proteoliposome. AIM The aim was to assessing the safety of AFCo1 by single and repeated doses in Sprague Dawley rats. MATERIALS AND METHODS Rats were grouped for treatment with AFCo1, placebo formulation or control. The first study was a single intranasal dose of 100 μl and monitoring body weight, water, and food intakes as well as clinical symptoms. Fourteen days later the rats were killed and anatomopathological studies were conducted. In a second study, four similar doses of the test substance were instilled every 5 days. Clinical observations were carried out as for the single dose study and a number of rats from each group were killed 3 and 14 days after the last dose in order to conduct hematological, hemochemical, and anatomopathological studies. RESULTS No variable showed differences of toxicological relevance; the histological changes found were mild and similarly frequently in the three groups. According to the irritability index calculated form histology of the nasal region, AFCo1 was also classified as nonirritating. CONCLUSION AFCo1 is potentially safe for human use by nasal route as evidenced by the absence of local and systemic signs of toxicity in Sprague Dawley rats.
Collapse
Affiliation(s)
| | - Sergio Sifontes-Rodríguez
- Department of Animal Model and Immunology, Vice Presidency of Research, Finlay Institute, Havana, Cuba
| | | | - Tamara Hernández-Salazar
- Department of Animal Model and Immunology, Vice Presidency of Research, Finlay Institute, Havana, Cuba
| | - Mildrey Fariñas-Medina
- Department of Animal Model and Immunology, Vice Presidency of Research, Finlay Institute, Havana, Cuba
| | - Oliver Pérez
- Department of Animal Model and Immunology, Vice Presidency of Research, Finlay Institute, Havana, Cuba
| |
Collapse
|
26
|
Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R, Fernandez S, Reyes G, Alvarez N, Garcia MA, Sarmiento ME, Norazmi MN, Perez Quinoy JL, Acosta A. Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine 2011; 29:6236-41. [PMID: 21736914 DOI: 10.1016/j.vaccine.2011.06.077] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Revised: 06/18/2011] [Accepted: 06/21/2011] [Indexed: 02/06/2023]
Abstract
Proteoliposomes (PL) obtained from Mycobacterium smegmatis (Ms) were evaluated for their capacity to elicit cross-reactive responses against Mycobacterium tuberculosis (Mtb) antigens in BALB/c mice. Animals immunized with PL adjuvanted with alum (PL-AL) or Freund's Incomplete Adjuvant (PL-IFA) showed significant IgG responses against the PL as well as total Ms lipids. Both groups of animals also showed significant IgG responses against BCG, but only animals immunized with PL-AL produced significant IgG responses against soluble cell wall proteins (SCWP) or whole cell lysate (WCL) of Mtb. Significant DTH responses against WCL were observed in both groups of animals after 24 h, but only PL-AL-immunized mice showed significant DTH responses after 48 h and 72 h. PL-Ms are capable of eliciting cross-reactive humoral and cellular responses against Mtb antigens and thus may be a potential vaccine strategy against tuberculosis.
Collapse
|
27
|
Epand RF, Mor A, Epand RM. Lipid complexes with cationic peptides and OAKs; their role in antimicrobial action and in the delivery of antimicrobial agents. Cell Mol Life Sci 2011; 68:2177-88. [PMID: 21573783 PMCID: PMC11114973 DOI: 10.1007/s00018-011-0711-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Revised: 04/26/2011] [Accepted: 04/26/2011] [Indexed: 12/31/2022]
Abstract
Antimicrobial agents are toxic to bacteria by a variety of mechanisms. One mechanism that is very dependent on the lipid composition of the bacterial membrane is the clustering of anionic lipid by cationic antimicrobial agents. Certain species of oligo-acyl-lysine (OAK) antimicrobial agents are particularly effective in clustering anionic lipids in mixtures mimicking the composition of bacterial membranes. The clustering of anionic lipids by certain cationic antimicrobial agents contributes to the anti-bacterial action of these agents. Bacterial membrane lipids are a determining factor, resulting in some species of bacteria being more susceptible than others. In addition, lipids can be used to increase the effectiveness of antimicrobial agents when administered in vivo. Therefore, we review some of the structures in which lipid mixtures can assemble, to more effectively be utilized as antimicrobial delivery systems. We describe in more detail the complexes formed between mixtures of lipids mimicking bacterial membranes and an OAK and their usefulness in synergizing with antibiotics to overcome bacterial multidrug resistance.
Collapse
Affiliation(s)
- Raquel F Epand
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8N 3Z5, Canada.
| | | | | |
Collapse
|
28
|
Jung ID, Jeong SK, Lee CM, Noh KT, Heo DR, Shin YK, Yun CH, Koh WJ, Akira S, Whang J, Kim HJ, Park WS, Shin SJ, Park YM. Enhanced Efficacy of Therapeutic Cancer Vaccines Produced by Co-Treatment with Mycobacterium tuberculosis Heparin-Binding Hemagglutinin, a Novel TLR4 Agonist. Cancer Res 2011; 71:2858-70. [DOI: 10.1158/0008-5472.can-10-3487] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Romeu B, González E, del Campo J, Acevedo R, Zayas C, Valdés Y, Cabrera O, Cuello M, Balboa J, Lastre M, Pérez O. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1. Can J Microbiol 2011; 57:256-61. [DOI: 10.1139/w11-002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Mucosal immune responses are an early and important line of defense against pathogens. The current understanding of the mucosal immune system allows us to consider the use of nasal immunization for induction of antigen-specific immune responses at the mucosal surface and the systemic compartment. Mucosal adjuvants are key for developing novel mucosal vaccines and represent 1 approach to improving mucosal and systemic immunity. However, few mucosal vaccine adjuvants are currently approved for human use. Neisseria meningitidis B proteoliposome-derived cochleate (AFCo1 — Adjuvant Finlay Cochleate 1) has been demonstrated to be a potent mucosal adjuvant. The present work demonstrates that intranasal immunization of 3 doses of tetanus toxoid (TT) coadministered with AFCo1 in mice promotes high systemic and mucosal responses. The anti-TT IgG serum titers and the mucosal anti-TT IgA in saliva and vaginal wash were significantly higher than TT alone. The analysis of antibody subclasses showed that intranasal administration of AFCo1 + TT induced not only IgG1 but also IgG2a anti-TT antibodies at levels comparable to those obtained with TT vaccine (vax-TET). These data support the fact that AFCo1 is a potent mucosal adjuvant in nasal immunization to a coadministered protein antigen.
Collapse
Affiliation(s)
- Belkis Romeu
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Elyzabeth González
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Judith del Campo
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Reynaldo Acevedo
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Caridad Zayas
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Yolanda Valdés
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Osmir Cabrera
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Maribel Cuello
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Julio Balboa
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Miriam Lastre
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| | - Oliver Pérez
- Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
- Molecular Biology Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
- Biomodels Department, Finlay Institute, Calle 17 esquina 198
Rpto Siboney, Havana 11600, Cuba
| |
Collapse
|
30
|
|
31
|
Giordano D, Li C, Suthar MS, Draves KE, Ma DY, Gale M, Clark EA. Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses. J Leukoc Biol 2010; 89:443-55. [PMID: 21178115 DOI: 10.1189/jlb.0610329] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Using NOS2 KO mice, we investigated the hypothesis that NO modulation of BM-DC contributes to the NO-mediated control of Th1 immune responses. BM-DCs from NOS2 KO mice, compared with WT BM-DCs, have enhanced survival and responsiveness to TLR agonists, develop more Ly6C(hi)PDCA1(+) DCs that resemble inflammatory DCs and produce high levels of inflammatory cytokines. Also, compared with WT-infected mice, NOS2 KO mice infected with WNV showed enhanced expansion of a similar inflammatory Ly6C(hi)PDCA1(+) DC subset. Furthermore, in contrast to WT DCs, OVA-loaded NOS2 KO BM-DCs promoted increased IFN-γ production by OTII CD4(+) T cells in vitro and when adoptively transferred in vivo. The addition of a NO donor to NOS2 KO BM-DCs prior to OTII T cells priming in vivo was sufficient to revert Th1 immune responses to levels induced by WT BM-DCs. Thus, autocrine NO effects on maturation of inflammatory DCs and on DC programming of T cells may contribute to the protective role of NO in autoimmune diseases and infections. Regulating NO levels may be a useful tool to shape beneficial immune responses for DC-based immunotherapy.
Collapse
Affiliation(s)
- Daniela Giordano
- Department of Immunology, University of Washington, Box 357330, 1959 N.E. Pacific St., Seattle, WA 98195, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol 2010; 31:429-35. [PMID: 20880743 DOI: 10.1016/j.it.2010.08.005] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2010] [Revised: 08/11/2010] [Accepted: 08/18/2010] [Indexed: 01/08/2023]
Abstract
Toll-like receptor (TLR) adjuvants are capable of driving T cell immunity. The TLR4 agonist LPS activates antigen-presenting cells through myeloid differentiation primary response gene 88 (MyD88) and TIR domain-containing adaptor inducing interferon-beta (TRIF)-dependent signaling pathways, initiating CD4 T helper cell clonal expansion and differentiation. Lipopolysaccharide (LPS) supports the development of diverse T helper (Th) lineages depending on the tissue microenvironment. For instance, peripheral immunization with LPS drives Th1 priming in lymphoid tissue and Th17 priming in the gut. This could be due to commensal bacteria inducing Th17-stabilizing cytokines within the intestinal lamina propria. Here, we detail how the response to LPS stimulates CD4 T cell priming in lymphoid tissue and the intestinal mucosa. How this knowledge might be exploited to target specific features of T cell immunity by vaccine adjuvants is also considered.
Collapse
|
33
|
Livne L, Epand RF, Papahadjopoulos-Sternberg B, Epand RM, Mor A. OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J 2010. [PMID: 20720156 DOI: 10.1096/fj.10.167809] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Antibiotic resistance has become a worldwide medical problem. To find new ways of overcoming this phenomenon, we investigated the role of the membrane-active oligo-acyl-lysyl (OAK) sequence C(12)K-7α(8), in combination with essentially ineffective antibiotics. Determination of minimal inhibitory concentration (MIC) against gram-negative multidrug-resistant strains of Escherichia coli revealed combinations with sub-MIC OAK levels that acted synergistically with several antibiotics, thus lowering their MICs by several orders of magnitude. To shed light into the molecular basis for this synergism, we used both mutant strains and biochemical assays. Our results suggest that bacterial sensitization to antibiotics was derived mainly from the OAK's capacity to overcome the efflux-enhanced resistance mechanism, by promoting backdoor entry of otherwise excluded antibiotics. To facilitate simultaneous delivery of the pooled drugs to an infection site, we developed a novel OAK-based cochleate system with demonstrable stability in whole blood. To assess the potential therapeutic use of such cochleates, we performed preliminary experiments that imitate systemic treatment of neutropenic mice infected with lethal inoculums of multidrug resistance E. coli. Single-dose administration of erythromycin coencapsulated in OAK-based cochleates has decreased drug toxicity and increased therapeutic efficacy in a dose-dependent manner. Collectively, our findings suggest a potentially useful approach for fighting efflux-enhanced resistance mechanisms.
Collapse
Affiliation(s)
- L Livne
- Department of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa, Israel
| | | | | | | | | |
Collapse
|
34
|
Livne L, Epand RF, Papahadjopoulos-Sternberg B, Epand RM, Mor A. OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J 2010; 24:5092-101. [PMID: 20720156 DOI: 10.1096/fj.10-167809] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Antibiotic resistance has become a worldwide medical problem. To find new ways of overcoming this phenomenon, we investigated the role of the membrane-active oligo-acyl-lysyl (OAK) sequence C(12)K-7α(8), in combination with essentially ineffective antibiotics. Determination of minimal inhibitory concentration (MIC) against gram-negative multidrug-resistant strains of Escherichia coli revealed combinations with sub-MIC OAK levels that acted synergistically with several antibiotics, thus lowering their MICs by several orders of magnitude. To shed light into the molecular basis for this synergism, we used both mutant strains and biochemical assays. Our results suggest that bacterial sensitization to antibiotics was derived mainly from the OAK's capacity to overcome the efflux-enhanced resistance mechanism, by promoting backdoor entry of otherwise excluded antibiotics. To facilitate simultaneous delivery of the pooled drugs to an infection site, we developed a novel OAK-based cochleate system with demonstrable stability in whole blood. To assess the potential therapeutic use of such cochleates, we performed preliminary experiments that imitate systemic treatment of neutropenic mice infected with lethal inoculums of multidrug resistance E. coli. Single-dose administration of erythromycin coencapsulated in OAK-based cochleates has decreased drug toxicity and increased therapeutic efficacy in a dose-dependent manner. Collectively, our findings suggest a potentially useful approach for fighting efflux-enhanced resistance mechanisms.
Collapse
Affiliation(s)
- L Livne
- Department of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa, Israel
| | | | | | | | | |
Collapse
|
35
|
Del Campo J, Lindqvist M, Cuello M, Bäckström M, Cabrerra O, Persson J, Perez O, Harandi AM. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 2010; 28:1193-200. [DOI: 10.1016/j.vaccine.2009.11.035] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2009] [Revised: 11/10/2009] [Accepted: 11/11/2009] [Indexed: 02/06/2023]
|
36
|
A vaccine against S. pyogenes: Design and experimental immune response. Methods 2009; 49:316-21. [DOI: 10.1016/j.ymeth.2009.03.024] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Revised: 03/05/2009] [Accepted: 03/09/2009] [Indexed: 11/17/2022] Open
|
37
|
Ferro VA, Pérez O. Adjuvant strategies required for targeting mucosal tissues. Methods 2009; 49:299-300. [DOI: 10.1016/j.ymeth.2009.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Accepted: 10/20/2009] [Indexed: 11/15/2022] Open
|
38
|
Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 2009; 27:3643-9. [DOI: 10.1016/j.vaccine.2009.03.040] [Citation(s) in RCA: 120] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2008] [Revised: 03/16/2009] [Accepted: 03/17/2009] [Indexed: 11/23/2022]
|
39
|
Campo JD, Zayas C, Romeu B, Acevedo R, González E, Bracho G, Cuello M, Cabrera O, Balboa J, Lastre M. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods 2009; 49:301-8. [PMID: 19410000 DOI: 10.1016/j.ymeth.2009.03.025] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2009] [Revised: 02/27/2009] [Accepted: 03/09/2009] [Indexed: 11/25/2022] Open
Abstract
Most pathogens either invade the body or establish infection in mucosal tissues and represent an enormous challenge for vaccine development by the absence of good mucosal adjuvants. A proteoliposome-derived adjuvant from Neisseria meningitidis serogroup B (AFPL1, Adjuvant Finlay Proteoliposome 1) and its derived cochleate form (Co, AFCo1) contain multiple pathogen-associated molecular patterns as immunopotentiators, and can also serve as delivery systems to elicit a Th1-type immune response. The present studies demonstrate the ability of AFPL1and AFCo1 to induce mucosal and systemic immune responses by different mucosal immunizations routes and significant adjuvant activity for antibody responses of both structures: a microparticle and a nanoparticle with a heterologous antigen. Therefore, we used female mice immunized by intragastric, intravaginal, intranasal or intramuscular routes with both structures alone or incorporated with ovalbumin (OVA). High levels of specific IgG antibody were detected in all sera and in vaginal washes, but specific IgA antibody in external secretions was only detected in mucosally immunized mice. Furthermore, antigen specific IgG1 and IgG2a isotypes were all induced. AFPL1 and AFCo1 are capable of inducing IFN-gamma responses, and chemokine secretions, like MIP-1alpha and MIP-1beta. However, AFCo1 is a better alternative to induce immune responses at mucosal level. Even when we use a heterologous antigen, the AFCo1 response was better than with AFPL1 in inducing mucosal and systemic immune responses. These results support the use of AFCo1 as a potent Th1 inducing adjuvant particularly suitable for mucosal immunization.
Collapse
Affiliation(s)
- Judith Del Campo
- Immunology Department, Finlay Institute, PO Box 16017, Havana, Cuba.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sharma S, Mukkur T, Benson HA, Chen Y. Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate Systems. J Pharm Sci 2009; 98:812-43. [DOI: 10.1002/jps.21493] [Citation(s) in RCA: 115] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
41
|
Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malar J 2009; 8:35. [PMID: 19250541 PMCID: PMC2662867 DOI: 10.1186/1475-2875-8-35] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2008] [Accepted: 02/27/2009] [Indexed: 11/28/2022] Open
Abstract
Background Whilst a large number of malaria antigens are being tested as candidate malaria vaccines, a major barrier to the development of an effective vaccine is the lack of a suitable human adjuvant capable of inducing a strong and long lasting immune response. In this study, the ability of AFCo1, a potent T and B cell adjuvant based on cochleate structures derived from meningococcal B outer membrane proteoliposomes (MBOMP), to boost the immune response against two Plasmodium falciparum antigens, merozoite surface protein 4 (MSP4) and 5 (MSP5), was evaluated. Methods Complete Freund's adjuvant (CFA), which is able to confer protection against malaria in animal MSP4/5 vaccine challenge models, was used as positive control adjuvant. MSP4 and 5-specific IgG, delayed-type hypersensitivity (DTH), T-cell proliferation, and cytokine production were evaluated in parallel in mice immunized three times intramuscularly with MSP4 or MSP5 incorporated into AFCo1, synthetic cochleate structures, CFA or phosphate buffered saline. Results AFCo1 significantly enhanced the IgG and T-cell response against MSP4 and MSP5, with a potency equivalent to CFA, with the response being characterized by both IgG1 and IgG2a isotypes, increased interferon gamma production and a strong DTH response, consistent with the ability of AFCo1 to induce Th1-like immune responses. Conclusion Given the proven safety of MBOMP, which is already in use in a licensed human vaccine, AFCo1 could assist the development of human malaria vaccines that require a potent and safe adjuvant.
Collapse
Affiliation(s)
- Gustavo Bracho
- Department of Immunology, Finlay Institute, Havana City, Cuba.
| | | | | | | | | | | |
Collapse
|
42
|
Mann JFS, Acevedo R, Campo JD, Pérez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev Vaccines 2009; 8:103-12. [PMID: 19093777 DOI: 10.1586/14760584.8.1.103] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Antigens administered via the oral and, to a lesser extent, the nasal route are potentially able to invoke tolerance, resulting in a nonreactive immune response. This has been a hurdle for mucosal vaccine development and yet the desire to induce protective local and systemic responses, with pain-free and more convenient products, has been the impetus driving mucosal vaccine R&D. Nevertheless, few mucosal vaccines have reached the marketplace and products are still treated with caution, particularly where live organisms are utilized. In this review, we examine the use of delivery systems with adjuvant properties as key components in a vaccine strategy that does not require the use of live vectors to overcome tolerance and have exemplified their success in mucosal vaccines, concentrating on the nasal and oral routes of administration.
Collapse
|
43
|
Pérez JL, Acevedo R, Callicó A, Fernández Y, Cedré B, Año G, González L, Falero G, Talavera A, Pérez O, García L. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine 2008; 27:205-12. [PMID: 18996426 DOI: 10.1016/j.vaccine.2008.10.052] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2008] [Revised: 10/15/2008] [Accepted: 10/20/2008] [Indexed: 02/03/2023]
Abstract
A vaccine candidate against the enteric pathogen Vibrio cholerae was developed based on a proteoliposome (PL) formulation using a wild type strain C7258, V. cholerae O1, El Tor Ogawa as part of strategy to develop a combined formulation against enteric diseases preventable by the stimulation of the mucosal immune system. A detergent extraction method was applied to obtain the PL. Scanning electron microscopy and molecular exclusion chromatography showed the presence of two PL populations. Photon correlation spectroscopy studies were then carried out to evaluate the size (169.27+/-3.85nm), polydispersity (0.410) and zeta potential (-23.28+/-1.21mV) of the PL. SDS-PAGE and Western blot analysis revealed the presence of lipopolysaccharide (LPS), mannose-sensitive haemagglutinin (MSHA) and a range of outer membrane proteins, including OmpU. BALB/c mice were immunized intranasally with two doses of PL containing 25mug of LPS each 28 days apart. The mice showed high anti-LPS IgG titres (3.36+/-0.235) and vibriocidal antibodies (3.70+/-0.23) after two weeks from last dose. These results show for the first time that PL can be obtained from V. cholerae O1 and when administer by intranasal route has the potential to protect against this pathogen.
Collapse
Affiliation(s)
- José Luis Pérez
- Instituto Finlay, Centro de Investigación y Producción de Vacunas, Ave. 27, No. 19805, La Lisa, A. P. 16017 Cod. 11600, Ciudad de La Habana, Cuba.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
|
45
|
|
46
|
|
47
|
Pajón R, Niebla O, Yero D, Pérez O, Cabrera O, Findlow J, Balmer P, Borrow R. On the neisserial vaccine quest: Neisseria Vaccines 2007. Expert Rev Anti Infect Ther 2007; 5:545-50. [PMID: 17678419 DOI: 10.1586/14787210.5.4.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Rolando Pajón
- Meningococcal Research Department, Center for Genetic Engineering and Biotechnology, Cubanacán Havana, Cuba.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, Balboa J, Acevedo R, Zayas C, Gil D, Mora N, González D, Pérez R, González E, Barberá R, Fajardo EM, Sierra G, Solís RL, Campa C. New Vaccines Require Potent Adjuvants like AFPL1 and AFCo1. Scand J Immunol 2007; 66:271-7. [PMID: 17635804 DOI: 10.1111/j.1365-3083.2007.01981.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Neisseria meningitidis B proteoliposome (AFPL1 when used as adjuvant) and its derivative-Cochleate (AFCo1) contain immunopotentiating and immunomodulating properties and delivery system capacities required for a good adjuvant. Additionally, they contain meningococcal protective antigens and permit packaging of other antigens and pathogen-associated molecular patterns (PAMP). Consequently, we hypothesized that they would function as good vaccine adjuvants for their own antigens and also for non-related antigens. AFPL1 is a detergent-extracted outer membrane vesicle of N. meningitidis B transformed into AFCo1 in calcium environment. Both are produced at Finlay Institute under good manufacture practices (GMP) conditions. We show their exceptional characteristics: combining in the same structure, the potentiator activity, polarizing agents and delivery system capacities; presenting multimeric protein copies; containing multiprotein composition and multi and synergistic PAMP components; acting with incorporated or co-administrated antigens; inducing type I IFN-gamma and IL-12 cytokines suggesting the stimulation of human plasmocytoid precursor and conventional dendritic cells, respectively, inducing a preferential Th1 immune response with TCD4(+), TCD8(+), cross-presentation and cytotoxic T-lymphocyte (CTL) in vivo responses; and functioning by parenteral and mucosal routes. AFPL1-AFCo1 protective protein constitutions permit per se their function as a vaccine. In addition to Phase IV Men BC vaccine, AFPL1 has ended the preclinical stage in an allergy vaccine and is concluding the preclinical stage of a nasal meningococcal vaccine. In conclusion, AFPL1 and AFCo1 induced signal 1, 2 and 3 polarizing to a Th1 (including CTL) response when they acted directly as vaccines or were used as adjuvants with incorporated or co-administered antigens by parenteral or mucosal routes. Both are very promising adjuvants.
Collapse
Affiliation(s)
- O Pérez
- Immunology Department, Finlay Institute, Havana City, Cuba.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Uli L, Castellanos-Serra L, Betancourt L, Domínguez F, Barberá R, Sotolongo F, Guillén G, Pajón Feyt R. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2006; 6:3389-99. [PMID: 16673438 DOI: 10.1002/pmic.200500502] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Neisseria meningitidis is a Gram-negative bacterium responsible for significant mortality worldwide. While effective polysaccharides-based vaccines exist against serogroups A, C, W135, and Y, no similar vaccine is suitable for children under 4 years against disease caused by serogroup B strains. Therefore, major vaccine efforts against this serogroup are based on outer membrane vesicles (OMVs), containing major outer membrane proteins. The OMV-based vaccine produced by the Finlay Institute in Cuba (VA-MENGOC-BC) contributed to the rapid decline of the epidemic in this Caribbean island. While the content of major proteins in this vaccine has been discussed, no detailed work of an outer membrane proteomic map of this, or any other, commercially available OMV-derived product has been published so far. Since OMVs exhibit a large bias toward a few major proteins and usually contain a high content of lipids, establishing the adequate conditions for high resolution, 2-DE of this kind of preparation was definitely a technical challenge. In this work, 2-DE and MS have been used to generate a proteomic map of this product, detailing the presence of 31 different proteins, and it allows the identification of new putative protective protein components it contains.
Collapse
Affiliation(s)
- Liliam Uli
- Finlay Institute, Serum and Vaccines Production Center, Habana, Cuba
| | | | | | | | | | | | | | | |
Collapse
|